High Expectations During the Trump Administration
Brian Malkin, Chair of the Food, Drug and Cosmetic Law Section, and Bethany Hills, a Member of the Section Executive Committee, discuss numerous expectations for the FDA under the Trump Administration, and outline how the Section will prepare practitioners for changes.
This premium content is reserved for New York Law Journal subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now